GLP-1 Medications for Children Show Nutritional Deficiency Risk Despite Weight Loss Benefits
New research warns that children taking GLP-1 medications like Ozempic and Saxenda for weight loss or diabetes may face overlooked nutritional deficiencies, prompting calls for closer monitoring during treatment.
What Happened
A new analysis published in early September 2026 has raised important safety concerns about the use of GLP-1 receptor agonist medications in children. Researchers found that while these drugs—including semaglutide (Victoza, Saxenda, Ozempic), dulaglutide (Trulicity), and tirzepatide (Mounjaro, Zepbound)—are effective for weight loss and glycemic control, they may pose an overlooked risk of nutritional deficiencies in pediatric patients.
The Mechanism of Concern
GLP-1 medications work by suppressing appetite and slowing gastric emptying, leading to reduced caloric intake and improved blood sugar control. However, this mechanism also significantly reduces overall food consumption. In children and adolescents, whose bodies are actively growing and developing, this substantial reduction in nutrient intake could compromise essential mineral and vitamin absorption. The concern is particularly acute for nutrients critical to bone development, immune function, and cognitive growth.
Clinical Implications for Young Patients
Children prescribed GLP-1 medications for type 2 diabetes, prediabetes, or obesity require enhanced nutritional monitoring. Healthcare providers are advised to implement regular screening for deficiencies in key nutrients including Vitamin B12, iron, calcium, and other micronutrients. Supplementation may be necessary for some patients to prevent long-term developmental complications. The findings suggest that benefits of weight loss and metabolic improvement must be balanced against potential nutritional risks in this vulnerable population.
Recommendations Moving Forward
Pediatric endocrinologists and primary care physicians should establish comprehensive monitoring protocols for children on GLP-1 therapy. Parents and caregivers must be counseled about the importance of nutrient-dense foods and supplementation. Further research is needed to determine optimal monitoring intervals and supplementation strategies. Regulatory agencies are expected to review labeling and clinical guidance for pediatric GLP-1 use.